Health Care [ 12/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma.
In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia.
The company has license and collaboration agreements with Pfizer Inc., Servier, CellectisS. A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3.
The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.28 Increased by +26.32% | -0.41 Increased by +31.71% |
| Mar 12, 25 | -0.28 Increased by +34.88% | -0.32 Increased by +13.42% |
| Nov 7, 24 | -0.32 Increased by +13.51% | -0.33 Increased by +3.03% |
| Aug 7, 24 | -0.35 Increased by +33.96% | -0.35 |
| May 13, 24 | -0.38 Increased by +44.12% | -0.41 Increased by +7.32% |
| Mar 14, 24 | -0.43 Increased by +34.85% | -0.45 Increased by +4.44% |
| Nov 2, 23 | -0.37 Increased by +36.21% | -0.52 Increased by +28.85% |
| Aug 2, 23 | -0.53 Decreased by -1.92% | -0.59 Increased by +10.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by -100.00% | -59.73 M Increased by +8.10% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | -22.00 K Increased by +50.00% | -59.94 M Increased by +33.12% | Increased by +272.45 K% Increased by +33.76% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -66.29 M Decreased by -6.43% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -66.36 M Increased by +16.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 22.00 K Decreased by -26.67% | -65.00 M Increased by +34.98% | Decreased by -295.45 K% Increased by +11.34% |
| Dec 31, 23 | -44.00 K Decreased by -193.62% | -89.62 M Increased by +5.51% | Increased by +203.69 K% Increased by +200.93% |
| Sep 30, 23 | 22.00 K Decreased by -55.10% | -62.29 M Increased by +25.09% | Decreased by -283.12 K% Decreased by -66.85% |
| Jun 30, 23 | 22.00 K Decreased by -74.42% | -79.23 M Decreased by -5.94% | Decreased by -360.15 K% Decreased by -314.14% |